|
|
News Breaks | | | | September 13, 2012 | | 08:31 EDT |  | SNT | Senesco announces first dose of SNS01-T in Cohort 2 of Phase 1b/2a study
Senesco Technologies reported that the first patient has been enrolled and dosing has been initiated in cohort 2 of its clinical trial with SNS01-T in multiple myeloma. SNS01-T was well tolerated and met the criteria for Stable Disease in 2 of the 3 evaluable patients that comprised cohort 1. The study is an open-label, multiple-dose, dose-escalation study, which is evaluating the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein. | |
|
News For SNT From The Last 14 Days Check below for free stories on SNT the last two weeks. |
|
|
| There are no results for SNT |
|
|
|
|
|
|
